Key facts
- This page summarizes Tina Marriott's Form 4 filing for RECURSION PHARMACEUTICALS, INC. (RXRX).
- 3 reported transactions and 6 derivative rows are listed below.
- Filing timestamp: 23 Feb 2024, 19:22.
Tina Marriott - 22 Feb 2024 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)
- Role
- President and COO
- Signature
- /s/Nathan Hatfield, attorney-in-fact
- Issuer symbol
- RXRX
- Transactions as of
- 22 Feb 2024
- Net transactions value
- -$110,680
- Form type
- 4
- Filing time
- 23 Feb 2024, 19:22:51 UTC
- Previous filing
- 16 Feb 2024
- Next filing
- 25 Mar 2024
- SEC
- View on sec.gov
Key filing fact
Tina Marriott filed Form 4 for RECURSION PHARMACEUTICALS, INC. (RXRX) on 23 Feb 2024.
Change
- Previous filing in this sequence was filed on 16 Feb 2024.
- Current net transaction value: -$110,680.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Transactions Table
RXRX
transaction
Class A Common Stock
Options Exercise
- Transaction value
- $8,480
- Shares
- +8,000
- Change %
- +1.3%
- Price
- $1.06
- Shares after
- 647,982
- Date
- 22 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
RXRX
transaction
Class A Common Stock
Sale
- Transaction value
- $119,160
- Shares
- -8,000
- Change %
- -1.2%
- Price
- $14.90
- Shares after
- 639,982
- Date
- 22 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
RXRX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -8,000
- Change %
- -1.6%
- Price
- $0.000000
- Shares after
- 496,000
- Date
- 22 Feb 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 8,000
- Exercise price
- $1.06
- Footnotes
- F4
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 434,122
- Date
- 22 Feb 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $8.55
- Footnotes
- F3
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 159,226
- Date
- 22 Feb 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $11.40
- Footnotes
- F5
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 4,784
- Date
- 22 Feb 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $11.40
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 150,000
- Date
- 22 Feb 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $2.48
- Footnotes
- F6
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 447,917
- Date
- 22 Feb 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $10.09
- Footnotes
- F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. |
| F2 | This transaction was executed in multiple trades at prices ranging from $14.42 to $15.19. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| F3 | The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |
| F4 | Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. |
| F5 | The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |
| F6 | One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date. |
| F7 | The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |